drugset
drugset / Trial / NCT00740246

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

NCT00740246 ↗

Phase 3 Completed 594 enrolled American Regent, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia

Timeline

Start
2005-07
Primary completion
2006-02
Completion
2006-05

Publications

  • Results Seid MH, Valaoras TG, Barish CF, Dinh Q. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.
  • Results Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Management 2007.

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 15 mg/kg Intravenous

Indications

anemia